Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity

References

• Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex function and altered muscle mechanics. Lancet Neurol. 2007 Aug;6(8):725–733.
   PubMed Web of Science ®Google Scholar
• Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013 Jan 15;80(3 Suppl 2):S13–S19.
   PubMed Web of Science ®Google Scholar
• Foley N, Pereira S, Salter K, et al. Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013 May;94(5):977–989.
   PubMed Web of Science ®Google Scholar
• Picelli A, Tamburin S, Gajofatto F, et al. Association between severe upper limb spasticity and brain lesion location in stroke patients. Biomed Res Int. 2014;2014:162754.
   PubMed Web of Science ®Google Scholar
• Paul SL, Sturm JW, Dewey HM, et al. Long-term outcome in the North East Melbourne Stroke Incidence Study: predictors of quality of life at 5 years after stroke. Stroke. 2005 Oct;36(10):2082–2086.
   PubMed Web of Science ®Google Scholar
• Wissel J, Muller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000 Jul;20(1):44–49.
   PubMed Web of Science ®Google Scholar
• Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009 Sep-Oct;32(5):259–265.
   PubMed Web of Science ®Google Scholar
• Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009 May;11(3):153–161.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001 Nov;8(6):559–565.
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395–400.
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000 Oct;31(10):2402–2406.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 6;70(19):1699–1706.
   PubMed Web of Science ®Google Scholar
• Simpson LL. Botulinum toxin: a deadly poison sheds its negative image. Ann Intern Med. 1996 Oct 1;125(7):616–617.
   PubMed Web of Science ®Google Scholar
• Jost WH, Benecke R, Hauschke D, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:1913–1926.
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):380–385.
   PubMed Web of Science ®Google Scholar
• Ward AB, Wissel J, Molteni F, et al. European consensus statement on the use of botulinum toxin type A in the management of adult spasticity. Acta Neurol Belg. 2003;Mar;103(1):39.
   PubMed Web of Science ®Google Scholar
• Ward AB, Aguilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity: a European consensus statement. J Rehabil Med. 2003 Mar;35(2):98–99.
   PubMed Web of Science ®Google Scholar
• Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009 Jan;41(1):13–25.
   PubMed Web of Science ®Google Scholar
• Ward AB, Aguilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity. A European consensus statement. Eura Medicophys. 2004 Jun;40(2):83–84.
   PubMedGoogle Scholar
• Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox((R))) and incobotulinumtoxinA (Xeomin ((R))) in an LD50 assay. J Neural Transm (Vienna). 2012 Jan;119(1):13–15.
   PubMed Web of Science ®Google Scholar
• Yun JY, Kim JW, Kim HT, et al. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. Mov Disord. 2015 Feb;30(2):206–213.
   PubMed Web of Science ®Google Scholar
• Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015 Mar;15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol. 2008 Dec;255(12):1932–1939.
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Kampe K, Bigalke H. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord. 2004;Mar;19(Suppl 8):S65–S67.
   PubMedGoogle Scholar
• Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015 Oct;262(10):2201–2213.
   PubMed Web of Science ®Google Scholar
• Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci. 2013 Jul;34(7):1043–1048.
   PubMed Web of Science ®Google Scholar
• Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport(R)) to incobotulinumtoxinA (Xeomin(R)) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015 Feb;47(2):183–186.
   PubMed Web of Science ®Google Scholar
• Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm. 2013 Mar;120(3):469–476.
   PubMed Web of Science ®Google Scholar
• Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med. 2013 Aug;49(4):483–489.
   PubMed Web of Science ®Google Scholar
• Barnes M, Schnitzler A, Medeiros L, et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies: a randomized parallel-group study. Acta Neurol Scand. 2010 Oct;122(4):295–302.
   PubMed Web of Science ®Google Scholar
• Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011 May;43(6):486–492.
   PubMed Web of Science ®Google Scholar
• Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ. 2014 Sep;17(9):618–625.
   PubMedGoogle Scholar
• Intiso D, Simone V, Di Rienzo F, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. NeuroRehabilitation. 2014;34(3):515–522.
   PubMed Web of Science ®Google Scholar
• Santamato A, Micello MF, Ranieri M, et al. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. J Neurol Sci. 2015 Mar 15;350(1–2):1–6.
   PubMed Web of Science ®Google Scholar
• Dressler D, Saberi FA, Kollewe K, et al. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm. 2015 Feb;122(2):327–333.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: https://www.clinicaltrials.gov.
   Google Scholar
• Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve. 2012 Sep;46(3):443–448.
   PubMed Web of Science ®Google Scholar
• Hesse S, Mach H, Frohlich S, et al. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Clin Rehabil. 2012 Mar;26(3):237–245.
   PubMed Web of Science ®Google Scholar
• Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10):3894–3902.
   PubMed Web of Science ®Google Scholar
• Gimenez DF, Gimenez JA. The typing of botulinal neurotoxins. Int J Food Microbiol. 1995 Sep;27(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kull S, Schulz KM, Weisemann J, et al. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS One. 2015;10(2):e0116381.
   PubMed Web of Science ®Google Scholar
• Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993 Sep 9;365(6442):160–163.
   PubMed Web of Science ®Google Scholar
• Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199–206.
   PubMed Web of Science ®Google Scholar
• Torii Y, Akaike N, Harakawa T, et al. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J Pharmacol Sci. 2011;117(4):275–285.
   PubMed Web of Science ®Google Scholar
• Torii Y, Goto Y, Nakahira S, et al. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies. Toxicon. 2014 Jan;77:114–120.
   PubMed Web of Science ®Google Scholar
• Kaji R. Clinical differences between A1 and A2 botulinum toxin subtypes. Toxicon. 2015 Sep 19;107:85–88.
   PubMed Web of Science ®Google Scholar
• Mukai Y, Shimatani Y, Sako W, et al. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals. Toxicon. 2014;81:32–36.
   PubMed Web of Science ®Google Scholar
• Rossetto O, Megighian A, Scorzeto M, et al. Botulinum neurotoxins. Toxicon. 2013 Jun 1;67:31–36.
   PubMed Web of Science ®Google Scholar
• Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve. 2009 Sep;40(3):374–380.
   PubMed Web of Science ®Google Scholar
• Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325–332.
   PubMedGoogle Scholar
• Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012 Apr 1;26(2):e1–e9.
   PubMedGoogle Scholar
• Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol. 2002;48(1):26–29.
   PubMed Web of Science ®Google Scholar
• Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30;23(10):1353–1360.
   PubMed Web of Science ®Google Scholar
• Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications. Mov Disord. 2010 Oct 15;25(13):2211–2218.
   PubMed Web of Science ®Google Scholar
• Muller K, Mix E, Adib Saberi F, et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009 May;116(5):579–585.
   PubMed Web of Science ®Google Scholar
• Mohammadi B, Kollewe K, Wegener M, et al. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm. 2009 Apr;116(4):437–441.
   PubMed Web of Science ®Google Scholar
• Hefter H, Spiess C, Rosenthal D. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm. 2014 May;121(5):513–519.
   PubMed Web of Science ®Google Scholar
• Hefter H, Hartmann C, Kahlen U, et al. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins: a single cohort 4-year follow-up study. BMJ Open. 2012;2(4):e000646–e000646.
   Web of Science ®Google Scholar
• Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002 May;81(5):355–363.
   PubMed Web of Science ®Google Scholar
• Gracies JM, Lugassy M, Weisz DJ, et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009 Jan;90(1):9–16 e2.
   PubMed Web of Science ®Google Scholar
• Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol. 2009 Dec 16;(Suppl 2):2–5.
   PubMed Web of Science ®Google Scholar
• Hulst JB, Minamoto VB, Lim MB, et al. Systematic test of neurotoxin dose and volume on muscle function in a rat model. Muscle Nerve. 2014 May;49(5):709–715.
   PubMed Web of Science ®Google Scholar
• Picelli A, Lobba D, Midiri A, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil. 2014 Mar;28(3):232–242.
   PubMed Web of Science ®Google Scholar
• Santamato A, Micello MF, Panza F, et al. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. J Neurol Sci. 2014 Dec 15;347(1–2):39–43.
   PubMed Web of Science ®Google Scholar
• Picelli A, Roncari L, Baldessarelli S, et al. Accuracy of botulinum toxin type A injection into the forearm muscles of chronic stroke patients with spastic flexed wrist and clenched fist: manual needle placement evaluated using ultrasonography. J Rehabil Med. 2014 Nov;46(10):1042–1045.
   PubMed Web of Science ®Google Scholar
• Giovannelli M, Borriello G, Castri P, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007 Apr;21(4):331–337.
   PubMed Web of Science ®Google Scholar
• Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 1998 Oct;12(5):381–388.
   PubMed Web of Science ®Google Scholar
• Brown M, Nicholson G, Ardila MC, et al. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J Neural Transm. 2013 Feb;120(2):291–298.
   PubMed Web of Science ®Google Scholar
• Simpson L. The life history of a botulinum toxin molecule. Toxicon. 2013 Jun;68:40–59.
   PubMed Web of Science ®Google Scholar
• Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008 Apr 2;28(14):3689–3696.
   PubMed Web of Science ®Google Scholar
• Jost WH, Kohl A, Brinkmann S, et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm. 2005 Jul;112(7):905–913.
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Muller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol. 2007 Mar-Apr;30(2):86–94.
   PubMed Web of Science ®Google Scholar
• Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005 Jun 14;64(11):1949–1951.
   PubMed Web of Science ®Google Scholar
• Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67(5):669–683.
   PubMed Web of Science ®Google Scholar
• Elovic EP, Munin MC, Kanovsky P, et al. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve. 2016 Mar;53(3):415–421.
   PubMed Web of Science ®Google Scholar
• Fiore P, Santamato A, Ranieri M, et al. Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201. Int J Immunopathol Pharmacol. 2012 Jan–Mar;25(1 Suppl):57S–62S.
   PubMedGoogle Scholar
• Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox((R))) and incobotulinumtoxinA (Xeomin ((R))). J Neural Transm (Vienna). 2014 Jan;121(1):29–31.
   PubMed Web of Science ®Google Scholar
• Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006 Mar;113(3):303–312.
   PubMed Web of Science ®Google Scholar
• Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol. 2014 Sep;34(3):233–236.
   PubMed Web of Science ®Google Scholar
• Chundury RV, Couch SM, Holds JB. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. Ophthal Plast Reconstr Surg. 2013 May-Jun;29(3):205–207.
   PubMed Web of Science ®Google Scholar
• Merz. Pharma UK Ltd. XEOMIN® 100 Units Summary of Product Characteristics [webpage on the Internet]. Electronic Medicine Compendium; 2014 [updated 2014 Jun 30; cited 2014 Dec 16]. Available from: http://www.medicines.org.uk/emc/medicine/20666
   Google Scholar
• Xeomin® (incobotulinumtoxinA) for injection, for intramuscular use [prescribing information]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2011 [cited 2014 Dec 16]. [database on the Internet]2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125360s045lbl.pdf
   Google Scholar
• Schnitzler A, Ruet A, Baron S, et al. Botulinum toxin A for treating spasticity in adults: costly for French hospitals? Ann Phys Rehabil Med. 2015 Oct;58(5):265–268.
   PubMedGoogle Scholar
• Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011 Sep;258(9):1670–1675.
   PubMed Web of Science ®Google Scholar
• Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm (Vienna). 2013 Mar;120(3):469–476.
   PubMed Web of Science ®Google Scholar
• Rahimi F, Bee C, Debicki D, et al. Effectiveness of BoNT A in Parkinson’s disease upper limb tremor management. Can J Neurol Sci. 2013 Sep;40(5):663–669.
   PubMed Web of Science ®Google Scholar